Circulating Galectin-3: A Prognostic Biomarker in Hepatocellular Carcinoma.

Saved in:
Bibliographic Details
Title: Circulating Galectin-3: A Prognostic Biomarker in Hepatocellular Carcinoma.
Authors: Chamseddine S; Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Yavuz BG; Department of Internal Medicine, University of Missouri, Columbia, MO, USA., Mohamed YI; Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Lee SS; Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Yao JC; Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Hu ZI; Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., LaPelusa M; Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Xiao L; Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Sun R; Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Morris JS; Department of Biostatistics, Epidemiology, and Informatics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA., Hatia RI; Department of Epidemiology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Hassan M; Department of Epidemiology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Duda DG; Steele Laboratories, Department of Radiation Oncology, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA., Diab M; Department of Hematology and Oncology, Winship Cancer Institute, Emory University, Atlanta, GA., Mohamed A; Division of Hematology and Oncology, Department of Medicine, University Hospitals Cleveland Medical Center, Cleveland, OH, USA., Nassar A; Department of Surgery, Emory University, Atlanta, GA, USA., Amin HM; Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.; MD Anderson Cancer Center UTHealth Graduate School of Biomedical Sciences, Houston, TX, USA., Kaseb AO; Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Source: Journal of immunotherapy and precision oncology [J Immunother Precis Oncol] 2024 Nov 01; Vol. 7 (4), pp. 255-262. Date of Electronic Publication: 2024 Nov 01 (Print Publication: 2024).
Publication Type: Journal Article
Journal Info: Publisher: Innovative Healthcare Institute Country of Publication: United States NLM ID: 101768397 Publication Model: eCollection Cited Medium: Internet ISSN: 2590-017X (Electronic) Linking ISSN: 2590017X NLM ISO Abbreviation: J Immunother Precis Oncol Subsets: PubMed not MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:2590-017X
DOI:10.36401/JIPO-24-6